| Michael S Cicchetti, MD | |
|
100 College Pkwy, Suite 100, Williamsville, NY 14221-6800 | |
| (434) 924-2047 | |
| Not Available |
| Full Name | Michael S Cicchetti |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 19 Years |
| Location | 100 College Pkwy, Williamsville, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164644183 | NPI | - | NPPES |
| 03110469 | Medicaid | NY |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Buffalo Spine Medicine And Rehab Pllc | 8921253089 | 14 |
News Archive
A team led by Pr. Marina Cavazzana conducted at Necker Children's Hospital, AP-HP and the Imagine Institute in October 2014 gene therapy in the context of a phase I clinical trial / II in a patient 13 years with severe sickle cell disease.
Vitamin A deficiency is the leading cause of preventable blindness in children. It also increases the risk of disease and death from severe infections, according to the World Health Organization.
"This week, heads of state, celebrities and CEOs will attend U.N. Secretary General Ban Ki-moon's 'Every Woman, Every Child' dinner in New York," an event that "will highlight the amazing contribution of the Global Fund to Fight AIDS, Tuberculosis and Malaria to the health of women and children in developing countries," Lucy Chesire, executive director and secretary to the board of TB ACTION Group, writes in the Huffington Post's "The Big Push" blog.
In a small clinical trial led by the Johns Hopkins Bloomberg School of Public Health, researchers say that a promising single-dose dengue vaccine, developed by scientists at the National Institutes of Health, was 100 percent effective in preventing human volunteers from contracting the virus, the most prevalent mosquito-borne virus in the world.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the Phase I clinical study assessing Inovio's PENNVAX-B DNA vaccine delivered using its proprietary electroporation technology in a preventive setting has fully completed the enrollment of 48 healthy volunteers. The multi-center study is being conducted by Inovio's clinical collaborator, the HIV Vaccine Trials Network (HVTN), at several clinical sites under a protocol designated HVTN-080.
› Verified 8 days ago
| Entity Name | Buffalo Spine Medicine & Rehab Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326394701 PECOS PAC ID: 8921253089 Enrollment ID: O20130222000013 |
News Archive
A team led by Pr. Marina Cavazzana conducted at Necker Children's Hospital, AP-HP and the Imagine Institute in October 2014 gene therapy in the context of a phase I clinical trial / II in a patient 13 years with severe sickle cell disease.
Vitamin A deficiency is the leading cause of preventable blindness in children. It also increases the risk of disease and death from severe infections, according to the World Health Organization.
"This week, heads of state, celebrities and CEOs will attend U.N. Secretary General Ban Ki-moon's 'Every Woman, Every Child' dinner in New York," an event that "will highlight the amazing contribution of the Global Fund to Fight AIDS, Tuberculosis and Malaria to the health of women and children in developing countries," Lucy Chesire, executive director and secretary to the board of TB ACTION Group, writes in the Huffington Post's "The Big Push" blog.
In a small clinical trial led by the Johns Hopkins Bloomberg School of Public Health, researchers say that a promising single-dose dengue vaccine, developed by scientists at the National Institutes of Health, was 100 percent effective in preventing human volunteers from contracting the virus, the most prevalent mosquito-borne virus in the world.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the Phase I clinical study assessing Inovio's PENNVAX-B DNA vaccine delivered using its proprietary electroporation technology in a preventive setting has fully completed the enrollment of 48 healthy volunteers. The multi-center study is being conducted by Inovio's clinical collaborator, the HIV Vaccine Trials Network (HVTN), at several clinical sites under a protocol designated HVTN-080.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael S Cicchetti, MD 100 College Pkwy, Suite 100, Williamsville, NY 14221-6800 Ph: (716) 626-0093 | Michael S Cicchetti, MD 100 College Pkwy, Suite 100, Williamsville, NY 14221-6800 Ph: (434) 924-2047 |
News Archive
A team led by Pr. Marina Cavazzana conducted at Necker Children's Hospital, AP-HP and the Imagine Institute in October 2014 gene therapy in the context of a phase I clinical trial / II in a patient 13 years with severe sickle cell disease.
Vitamin A deficiency is the leading cause of preventable blindness in children. It also increases the risk of disease and death from severe infections, according to the World Health Organization.
"This week, heads of state, celebrities and CEOs will attend U.N. Secretary General Ban Ki-moon's 'Every Woman, Every Child' dinner in New York," an event that "will highlight the amazing contribution of the Global Fund to Fight AIDS, Tuberculosis and Malaria to the health of women and children in developing countries," Lucy Chesire, executive director and secretary to the board of TB ACTION Group, writes in the Huffington Post's "The Big Push" blog.
In a small clinical trial led by the Johns Hopkins Bloomberg School of Public Health, researchers say that a promising single-dose dengue vaccine, developed by scientists at the National Institutes of Health, was 100 percent effective in preventing human volunteers from contracting the virus, the most prevalent mosquito-borne virus in the world.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the Phase I clinical study assessing Inovio's PENNVAX-B DNA vaccine delivered using its proprietary electroporation technology in a preventive setting has fully completed the enrollment of 48 healthy volunteers. The multi-center study is being conducted by Inovio's clinical collaborator, the HIV Vaccine Trials Network (HVTN), at several clinical sites under a protocol designated HVTN-080.
› Verified 8 days ago
Dr. Jafar Siddiqui, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 40 George Karl Blvd, Williamsville, NY 14221 Phone: 716-218-1000 Fax: 716-200-1857 | |
S. David Miller, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 5820 Main St, Williamsville, NY 14221 Phone: 716-633-7544 | |
Valerie Vullo, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 850 Hopkins Rd, Williamsville, NY 14221 Phone: 716-688-0075 | |
Megan Ziske, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 111 North Maplemere Road Suite 100, Williamsville, NY 14221 Phone: 716-204-3200 Fax: 716-204-4337 | |
Daniel M Salcedo, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 400 International Drive, Williamsville, NY 14221 Phone: 716-631-3555 Fax: 716-631-9525 | |
Dr. Irfan M. Elahi, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 40 George Karl Blvd, Williamsville, NY 14221 Phone: 716-218-1000 |